Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy

International Journal of Cancer

Volumn 95, Issue 3, 2001, Pages 135-139

  Lacombe, Louis ^a   Maillette, Alain ^a   Meyer, Francois ^a   Veilleux, Chantal ^a   Moore, Lynne ^a   Fradet, Yves ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

p21; Prostate cancer; PSA failure; Radical prostatectomy; Tumor marker

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P21; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RISK ASSESSMENT; SEMINAL VESICLE;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0035918536     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010520)95:3<135::AID-IJC1023>3.0.CO;2-3     Document Type: Article

References (34)

1. Parker SL, Tone T, Bolden S, Wingo PA. Cancer statistics, 1996. Cancer J Clin 1996;46:5-27.
2. McLaughlin JR, Fields ALA, Mao Y, Whylie B, Dryer D, Villeneuve G. Canadian cancer statistics 1999. Can Cancer Soc 1999;1:1-77.
3. Waga S, Hannon G, Beach D, Stilllman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond) 1994;369:574-8.
4. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54: 3391-5.
5. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc nat Acad Sci Wash 1995;92:5545-9.
6. El-Deiry WS, Tokino T. Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
7. WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene 1996; 13: 1831-7.
8. Waf1/Cip1 in fetal and adult tissues: simultaneous analysis with Ki-67 and p53. J clin Pathol 1997;50:645-53.
9. Waf1/Cip1 expression in normal human tissues. Amer J Pathol 1996;148:825-35.
10. Reuter VE, Melamed MR. The lower urinary tract. In: Sternberg SS. Diagnostic surgical pathology. New York: Raven Press. 1994;1767-805.
11. Bostwick DG. Grading prostate cancer. Amer J clin Pathol 1994;102: s38-56.
12. Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, Kitamura T. et al. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 1998; 29:778-83.
13. Metha CR, Patel NR. A network algorithm for performing Fisher's exact test r × c contingency tables. J Amer stat Assoc 1983;78:427-34.
14. Cox DR. Partial likelihood. Biometrika 1975;62:269-79.
15. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997;49:16-22.
16. Vaillancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Amer J surg Pathol 1996;20:86-93.
17. Soloway MS, Sharifi R, Wajsman Z, McLeod DG, Wood Jr DP, Puros-Baez AF. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bN×M0) prostate cancer. J Urol 1995;154:424-8.
18. Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36 month post-treatment PSA results. Urology 1999;53:757-63.
19. Meyer F. Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999;162:2024-8.
20. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. Urol Clin North Amer 1993;20:713-25.
21. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.
22. Byrne RL, Wilson Home CH, Robinson MC, Autzen P. Apakama I, Bishop RI, et al. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Brit J Urol 1997;79:190-5.
23. Osman I, Drobnjak M, Fazzari M. Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer. Impact on tumor progression. Clin Cancer Res 1999;8:2082-8.
24. WAF1 expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). The Prostate 1999;40:256-60.
25. Aaltomaa S, Liponnen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. The Prostate 1999;39:8-15.
26. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Develop 1995;9: 935-44.
27. Dulic V. Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76: 1013-23.
28. Sinicrope FA, Roddey G, Lemoine M, Ruan S, Stephens LC, Frazier ML, et al. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin cancer Res 1998;4:1251-61.
29. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 1998;43:964-70.
30. Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, Ishimaru G, et al. Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998;41: 68-74.
31. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Amer J respir Cell mol Biol 1998;18: 213-17.
32. Qin LF, Ng IO, Fan ST, Ng M. p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998;79:424-8.
33. Stein JP, Ginsberj DA, Grassfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer [see comments). J nat Cancer Inst 1998;90:1072-9.
34. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.